본문 바로가기
KERD
논문KCI 등재

Bone Marrow-Derived Mesenchymal Stem Cell Therapy as a Candidate Disease-Modifying Strategy in Parkinson’s Disease and Multiple System Atrophy

박현정|이필휴
대한신경과학회 (Korean Neurological Association)|2009.03|Journal of Clinical Neurology|제5권 제1호|pp. 1-10

1

조회

0

다운로드

3

인용

0

참고문헌

키워드

Parkinson’s diseasemesenchymal stem cellscell therapymultiple system atrophyneuroprotection.

초록

Parkinson’s disease (PD) and multiple system atrophy (MSA) are neurodegenerative diseases representative of α-synucleinopathies characterized pathologically by α-synuclein-abundant Lewy bodies and glial cytoplasmic inclusions, respectively. Embryonic stem cells, fetal mesencephalic neurons, and neural stem cells have been introduced as restorative strategies in PD animals and patients, but ethical and immunological problems as well as the serious side effects of tumorigenesis and disabling dyskinesia have limited clinical application of these stem cells. Meanwhile, cell therapy using mesenchymal stem cells (MSCs) is attractive clinically because these cells are free from ethical and immunological problems. MSCs are present in adult bone marrow and represent <0.01% of all nucleated bone marrow cells. MSCs are themselves capable of multipotency, differentiating under appropriate conditions into chondrocytes, skeletal myocytes, and neurons. According to recent studies, the neuroprotective effect of MSCs is mediated by their ability to produce various trophic factors that contribute to functional recovery, neuronal cell survival, and stimulation of endogenous regeneration and by immunoregulatory properties that not only inhibit nearly all cells participating in the immune response cell-cell-contact-dependent mechanism, but also release various soluble factors associated with immunosuppressive activity. However, the use of MSCs as neuroprotectives in PD and MSA has seldom been studied. Here we comprehensively review recent advances in the therapeutic roles of MSCs in PD and MSA, especially focusing on their neuroprotective properties and use in disease-modifying therapeutic strategies.

Abstract

Parkinson’s disease (PD) and multiple system atrophy (MSA) are neurodegenerative diseases representative of α-synucleinopathies characterized pathologically by α-synuclein-abundant Lewy bodies and glial cytoplasmic inclusions, respectively. Embryonic stem cells, fetal mesencephalic neurons, and neural stem cells have been introduced as restorative strategies in PD animals and patients, but ethical and immunological problems as well as the serious side effects of tumorigenesis and disabling dyskinesia have limited clinical application of these stem cells. Meanwhile, cell therapy using mesenchymal stem cells (MSCs) is attractive clinically because these cells are free from ethical and immunological problems. MSCs are present in adult bone marrow and represent <0.01% of all nucleated bone marrow cells. MSCs are themselves capable of multipotency, differentiating under appropriate conditions into chondrocytes, skeletal myocytes, and neurons. According to recent studies, the neuroprotective effect of MSCs is mediated by their ability to produce various trophic factors that contribute to functional recovery, neuronal cell survival, and stimulation of endogenous regeneration and by immunoregulatory properties that not only inhibit nearly all cells participating in the immune response cell-cell-contact-dependent mechanism, but also release various soluble factors associated with immunosuppressive activity. However, the use of MSCs as neuroprotectives in PD and MSA has seldom been studied. Here we comprehensively review recent advances in the therapeutic roles of MSCs in PD and MSA, especially focusing on their neuroprotective properties and use in disease-modifying therapeutic strategies.

참고문헌 (71)

  1. Moore DJ, "Molecular pathophysiology of Parkinson’s disease", Annu Rev Neurosci, 28, pp.57~87 (2005)
  2. von Bohlen, "Genes, proteins, and neurotoxins involved in Parkinson’s disease", Prog Neurobiol, 73, pp.151~177 (2004)
  3. Adler CH, "Nonmotor complications in Parkinson’s disease", Mov Disord, 20(11), pp.S23~S29 (2005)
  4. Palmer MR, "Intranigral transplantation of solid tissue ventral mesencephalon or striatal grafts induces behavioral recovery in 6- OHDA-lesioned rats", Brain Res, 890, pp.86~99 (2001)
  5. Lindvall O, "Stem cells for cell therapy in Parkinson’s disease", Pharmacol Res, 47, pp.279~287 (2003)
  6. Freed CR, "Transplantation of embryonic dopamine neurons for severe Parkinson’s disease", N Engl J Med, 344, pp.710~719 (2001)
  7. Olanow CW, "A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease", Ann Neurol, 54, pp.403~414 (2003)
  8. Poewe W, "Non-motor symptoms in Parkinson’s disease", Eur J Neurol, 15(1), pp.14~20 (2008)
  9. Braak H, "Invited Article: Nervous system pathology in sporadic Parkinson disease", Neurology, 70, pp.1916~1925 (2008)
  10. Braak H, "Stages in the development of Parkinson’s disease-related pathology", Cell Tissue Res, 318, pp.121~134 (2004)
  11. Lee PH, "Correlation between cardiac 123I-MIBG and odor identification in patients with Parkinson’s disease and multiple system atrophy", Mov Disord, 21, pp.1975~1977 (2006)
  12. Correia AS, "Stem cell-based therapy for Parkinson’s disease", Ann Med, 37, pp.487~498 (2005)
  13. Hagell P, "Dyskinesias following neural transplantation in Parkinson’s disease", Nat Neurosci, 5, pp.627~628 (2002)
  14. Björklund A, "Neural transplantation for the treatment of Parkinson’s disease", Lancet Neurol, 2, pp.437~445 (2003)
  15. Winkler C, "Cell transplantation in Parkinson’s disease: how can we make it work?", Trends Neurosci, 28, pp.86~92 (2005)
  16. Isacson O, "Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson’s disease by stem cells", Ann Neurol, 53(3), pp.S135~S146 (2003)
  17. Kordower JH, "Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease", Nat Med, 14, pp.504~506 (2008)
  18. Li JY, "Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation", Nat Med, 14, pp.501~503 (2008)
  19. Mendez I, "Dopamine neurons implanted into people with Parkinson’s disease survive without pathology for 14 years", Nat Med, 14, pp.507~509 (2008)
  20. Pittenger MF, "Multilineage potential of adult human mesenchymal stem cells", Science, 284, pp.143~147 (1999)
  21. Woodbury D, "Adult rat and human bone marrow stromal cells differentiate into neurons", J Neurosci Res, 61, pp.364~370 (2000)
  22. Minguell JJ, "Mesenchymal stem cells", Exp Biol Med, 226, pp.507~520 (2001)
  23. Bonuccelli U, "New pharmacologic horizons in the treatment of Parkinson disease", Neurology, 67, pp.S30~S38 (2006)
  24. Li Y, "Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery", Neurology, 59, pp.514~523 (2002)
  25. Mahmood A, "Marrow stromal cell transplantation after traumatic brain injury promotes cellular proliferation within the brain", Neurosurgery, 55, pp.1185~1193 (2004)
  26. Crigler L, "Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis", Exp Neurol, 198, pp.54~64 (2006)
  27. Arnhold S, "Human bone marrow stroma cells display certain neural characteristics and integrate in the subventricular compartment after injection into the liquor system", Eur J Cell Biol, 85, pp.551~565 (2006)
  28. Barry FP, "Mesenchymal stem cells: clinical applications and biological characterization", Int J Biochem Cell Biol, 36, pp.568~584 (2004)
  29. McGeer PL, "substantia nigra of Parkinson’s and Alzheimer’s disease brains", Neurology, 38, pp.1285~1291 (1988)
  30. Langston JW, "Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure", Ann Neurol, 46, pp.598~605 (1999)
  31. Ouchi Y, "Microglial activation and dopamine terminal loss in early Parkinson’s disease", Ann Neurol, 57, pp.168~175 (2005)
  32. Hunot S, "FcepsilonRII", CD23 is expressed in Parkinson’s disease and induces, in vitro, production of nitric oxide and tumor necrosis factoralpha in glial cells, 1999, pp.19, 3440~3447
  33. Nagatsu T, "Cytokines in Parkinson’s disease", J Neural Transm Suppl, pp.143~151 (2000)
  34. Gao HM, "Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons", J Neurosci, 22, pp.782~790 (2002)
  35. Cicchetti F, "Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging", Eur J Neurosci, 15, pp.991~998 (2002)
  36. Liberatore GT, "Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease", Nat Med, 5, pp.1403~1409 (1999)
  37. Krampera M, "Regenerative and immunomodulatory potential of mesenchymal stem cells", Curr Opin Pharmacol, 6, pp.435~441 (2006)
  38. Karussis D, "Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological", neurodegenerative diseases, 2008, pp.265, 131~135
  39. Nauta AJ, "Immunomodulatory properties of mesenchymal stromal cells", Blood, 110, pp.3499~3506 (2007)
  40. Zappia E, "Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy", Blood, 106, pp.1755~1761 (2005)
  41. Gerdoni E, "Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis", Ann Neurol, 61, pp.219~227 (2007)
  42. Guo J, "Anti-inflammation role for mesenchymal stem cells transplantation in myocardial infarction", Inflammation, 30, pp.97~104 (2007)
  43. Aubin N, "Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice", J Neurochem, 71, pp.1635~1642 (1998)
  44. Teismann P, "Cyclooxygenase- 2 is instrumental in Parkinson’s disease neurodegeneration", Proc Natl Acad Sci U S A, 통권 : 100, pp.5473~5478 (2003)
  45. Chen H, "Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease", Arch Neurol, 60, pp.1059~1064 (2003)
  46. Wahner AD, "Nonsteroidal antiinflammatory drugs may protect against Parkinson disease", Neurology, 69, pp.1836~1842 (2007)
  47. Chen J, "Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat", J Neurosci Res, 73, pp.778~786 (2003)
  48. Li Y, "Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine mouse model of Parkinson’s disease", Neurosci Lett, 316, pp.67~70 (2001)
  49. Stumm RK, "A dual role for the SDF-1", CXCR4 chemokine receptor system in adult brain: isoform-selective regulation of SDF-1 expression modulates CXCR4-dependent neuronal plasticity and cerebral leukocyte recruitment after focal ischemia, 2002, pp.22, 5865~5878
  50. Chamberlain G, "Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing", Stem Cells, 25, pp.2739~2749 (2007)
  51. Banisadr G, "Highly regionalized distribution of stromal cell-derived factor-1", CXCL12 in adult rat brain: constitutive expression in cholinergic, dopaminergic and vasopressinergic neurons, 2003, pp.18, 1593~1606
  52. Emborg ME, "Evaluation of animal models of Parkinson’s disease for neuroprotective strategies", J Neurosci Methods, 139, pp.121~143 (2004)
  53. McNaught KS, "Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease", Ann Neurol, 56, pp.149~162 (2004)
  54. Schapira AH, "Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons", Ann Neurol, 60, pp.253~255 (2006)
  55. Zeng BY, "Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats", Ann Neurol, 60, pp.248~252 (2006)
  56. Bové J, "Proteasome inhibition and Parkinson’s disease modeling", Ann Neurol, 60, pp.260~264 (2006)
  57. Kordower JH, "Failure of proteasome inhibitor administration to provide a model of Parkinson’s disease in rats and monkeys", Ann Neurol, 60, pp.264~268 (2006)
  58. Manning-Boğ AB, "Lack of nigrostriatal pathology in a rat model of proteasome inhibition", Ann Neurol, 60, pp.256~260 (2006)
  59. Park HJ, "Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson’s disease", J Neurochem, 107, pp.141~151 (2008)
  60. Tatton WG, "Apoptosis in Parkinson’s disease: signals for neuronal degradation", Ann Neurol, 53(3), pp.S61~S70 (2003)
  61. Olanow CW, "Ubiquitin-proteasome system and Parkinson’s disease", Mov Disord, 21, pp.1806~1823 (2006)
  62. Kim YJ, "Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action", Glia, 57, pp.13~23 (2009)
  63. Mareschi K, "Neural differentiation of human mesenchymal stem cells: Evidence for expression of neural markers and eag K+ channel types", Exp Hematol, 34, pp.1563~1572
  64. Blondheim NR, "Human mesenchymal stem cells express neural genes, suggesting a neural predisposition", Stem Cells Dev, 15, pp.141~164 (2006)
  65. Barzilay R, "Induction of human mesenchymal stem cells into dopamine-producing cells with different differentiation protocols", Stem Cells Dev, 17, pp.547~554 (2008)
  66. Offen D, "Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinson’s disease", J Neural Transm Suppl, 133, pp.143~ (2007)
  67. Ye M, "Therapeutic effects of differentiated bone marrow stromal cell transplantation on rat models of Parkinson’s disease", Parkinsonism Relat Disord, 13, pp.44~49 (2007)
  68. Wenning GK, "Multiple system atrophy", Lancet Neurol, 3, pp.93~103 (2004)
  69. Lee PH, "Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy", Clin Pharmacol Ther, 83, pp.723~730 (2008)
  70. Quinn N, "Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective?", Clin Pharmacol Ther, 83, pp.663~665 (2008)
  71. Whone AL, "Mesenchymal stem cells and neurodegenerative disease", Clin Pharmacol Ther, 85, pp.19~20 (2009)

이 간행물의 다른 논문 (8건)

Tinnitus: Characteristics, Causes, Mechanisms, and Treatments김태유, 이호원, 한병인, 임준성, 신경식pp. 11-19Epidemiology of Insomnia in Korean Adults: Prevalence and Associated Factors조용원, 신원철, 홍승봉, 김주한, 윤창호, Christopher J. Earleypp. 20-23Long-Term Durability of Percutaneous Transluminal Angioplasty in Patients with Symptomatic Middle Cerebral Artery Stenosis이승한, 김병채, 박만석, 조기현, 김명규, 김재규, 최성민, 윤웅, 김준태pp. 24-28The G2019S LRRK2 Mutation is Rare in Korean Patients with Parkinson’s Disease and Multiple System Atrophy김성연, 박성섭, 전범석, 조진환pp. 29-32Citicoline Protects Against Cognitive Impairment in a Rat Model of Chronic Cerebral Hypoperfusion강지승, 이현준, 김영인pp. 33-38
원문 보기